PARTNERSHIPS | One key factor for the success of this venture is the ability to screen and identify promising projects within the academic / early-stage ecosystem which are ripe for translational development and well-suited to value generation. Such projects will offer the potential of breakthrough therapeutic products capable of transforming treatment options for patients. MedXCell has developed positive relationships with institutions and individual researchers both to access current research results and to inspire new projects. MedXCell has already successfully collaborated with the SATT AxLR (Montpellier’s academic institutions Tech Transfer office on which MedXCell disposes of a right of first refusal) and Federal Institute of Technology in Lausanne (EPFL), Switzerland.

There is a gap at the academic / industrial interface that academic research and big pharma cannot fill because of their mutual inability to operate effectively in the translational phase of these projects. The co-designing phase is crucial so that researchers engage with industry executives that understand the needs and dynamics of translational technology and innovation development and who can plan and implement the metamorphosis of breakthrough ideas into viable breakthrough product concepts, with effective understanding and management of the attrition rate at this stage.